Rituximab-Dependent Cytotoxicity by Natural Killer Cells

CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

2002 • 5,269 citations

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1998 • 2,777 citations

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

2000 • 2,694 citations

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

1994 • 1,932 citations

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

2002 • 1,853 citations

Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity

2002 • 1,698 citations

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

2003 • 1,289 citations

High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR

2001 • 1,108 citations

Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study

1998 • 914 citations

FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype

1997 • 760 citations

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

1994 • 747 citations

A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.

1997 • 698 citations

The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex

2000 • 697 citations

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis

2000 • 576 citations

Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies

1998 • 576 citations

Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo

2003 • 557 citations

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

2001 • 533 citations

Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

1998 • 527 citations

Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma

2002 • 430 citations

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

2001 • 425 citations

The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus

2003 • 423 citations

Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc

2000 • 416 citations

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

2000 • 388 citations

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

2003 • 384 citations

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas

2003 • 355 citations

The Structure of a Human Type III Fcγ Receptor in Complex with Fc

2001 • 346 citations

Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s Macroglobulinemia

2005 • 258 citations

Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms

2000 • 251 citations

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

2001 • 220 citations

Immune evasion of tumor cells using membrane-bound complement regulatory proteins

1999 • 204 citations

Binding to CD20 by Anti-B1 Antibody or F(ab') 2 is sufficient for induction of apoptosis in B-cell lines

2002 • 188 citations

IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells

2002 • 173 citations

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

1994 • 169 citations

Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.

2000 • 158 citations

IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells

2002 • 154 citations

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 /neu-positive breast cancer cells

2001 • 152 citations

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma

1998 • 152 citations

Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.

2003 • 109 citations

Increased resistance to non-MHC-restricted cytotoxicity related to HLA A, B expression. Direct demonstration using beta 2-microglobulin-transfected Daudi cells.

1988 • 106 citations

Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells.

1993 • 104 citations

Trophoblast Cell Line Resistance to NK Lysis Mainly Involves an HLA Class I-Independent Mechanism

1999 • 97 citations

Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding.

1997 • 96 citations

Cloned and expressed human Fc receptor for IgG mediates anti-CD3-dependent lymphoproliferation.

1988 • 80 citations

Pharmacokinetically Guided Administration of Chemotherapeutic Agents

2000 • 66 citations

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

1994 • 60 citations

Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR

2003 • 59 citations

Compared TCR and CD3 epsilon expression on alpha beta and gamma delta T cells. Evidence for the association of two TCR heterodimers with three CD3 epsilon chains in the TCR/CD3 complex.

1995 • 44 citations

Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies

1998 • 44 citations

Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum.

1985 • 43 citations

The Efficiency Concept in Pharmacodynamics

1999 • 26 citations

FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype

1997 • 24 citations